Re-engineering Cardiovascular
Therapeutics Through Nitroxyl (HNO)
A next-generation approach to acute heart failure—unlocking a validated mechanism through advanced delivery engineering.
From instability to precision-controlled activation, we transform promising biology into viable therapeutics.
The Opportunity
A validated mechanism,
limited by formulation
Nitroxyl (HNO), long considered a derivative of nitric oxide, has emerged as a distinct and highly promising pharmacological entity with a uniquely favourable cardiovascular profile.
Unlike nitric oxide, HNO:
Uniquely suited for
Acute Decompensated
Heart Failure (ADHF)
The Core Challenge
You cannot formulate
instability
The failure of HNO therapeutics is not biological — it is chemical and formulation-driven. Three fundamental barriers have blocked translation.
Lessons From Clinical Failure
Where the industry
stalled
Previous development efforts demonstrated strong efficacy — but failed at the level of formulation, creating constraints that made real-world use impractical.
What history showed
Despite positive haemodynamic outcomes
Our Approach
From molecule failure to
delivery success
We approach HNO not as a discovery problem — but as a translational CMC challenge. The biology is validated; the engineering is the frontier.
Stabilising highly reactive intermediates throughout the formulation lifecycle
Controlling release kinetics to enable therapeutic windows
Engineering delivery environments that protect and activate with precision
The problem is repositioned
Biological discovery risk
Precision engineering of drug delivery systems
Platform Innovation
Engineering stability, control,
and targeting
Three complementary delivery engineering approaches — each addressing a distinct failure mode of previous HNO programmes.
Approach A
Nano-Encapsulation of HNO Donors
- Protects donor molecules from premature degradation
- Enables microenvironment control (e.g., internal pH buffering)
- Prevents systemic instability before target site
Approach B
Sustained-Release Delivery Systems
- Injectable depots (hydrogels, microspheres)
- Controlled, steady-state release profiles
- Eliminates need for continuous infusion
Approach C
Triggered Activation Systems
- Enzyme-responsive donors (esterase-mediated)
- ROS-triggered release in diseased myocardium
- Localised activation to reduce systemic toxicity
The Core Problem We Solve
Stability vs toxicity —
resolved through design
HNO sits at a critical intersection. Our platform addresses both dimensions through precise formulation engineering.
Too Unstable → Ineffective
Rapid decomposition in aqueous environments renders the molecule inactive before reaching its target site.
Too Reactive → Toxic
High thiol reactivity without targeting leads to non-specific systemic interactions and unacceptable toxicity.
Shield During Circulation
Encapsulation protects reactivity until target site
Enable Controlled Release
Precision kinetics at therapeutic concentrations
Target Diseased Tissue
ROS and enzyme-triggered activation in myocardium
SynapTx Advantage
Predicting stability
before it fails
HNO formulation challenges are fundamentally kinetic and thermodynamic problems — exactly where SynapTx provides a decisive computational advantage.
Problems SynapTx models
SynapTx enables
R&D Philosophy
Formulation-driven rescue.
Precision targeting.
Three interconnected principles that define how we approach the HNO problem — and all formulation-driven rescue programmes.
PRINCIPLE 01
Formulation-Driven Rescue
- Clinically validated but failed molecules
- Solving their delivery limitations precisely
- Unlocking latent therapeutic value
PRINCIPLE 02
Predictive CMC
- Using SynapTx to reduce experimental cycles
- Optimise stability upfront before synthesis
- Compress development timelines significantly
PRINCIPLE 03
Physiological Hijacking
- Target disease-specific environments
- Use endogenous transport pathways
- Enable predictable pharmacokinetics
Strategic Positioning
Where others see failure,
we see opportunity
The pharmaceutical industry has already done the hard work of validating the biology and clinical need. The gap that remains is precisely where we operate.
Already validated by industry
The biology of HNO as a cardiovascular agent
The clinical need in Acute Decompensated Heart Failure
Positive haemodynamic outcomes in controlled settings
What remains unsolved
This is precisely where we operate — and where our delivery engineering expertise creates decisive advantage.
Collaboration Call
Co-architect the next generation of
cardiovascular therapeutics
We invite pharmaceutical partners, research organisations, and strategic collaborators to advance this platform together.
We are not presenting
We are presenting
Partner With Us
Co-architect the next generation of
cardiovascular therapeutics
We are actively seeking pharmaceutical partners and research collaborators to advance this platform from resolved translational opportunity to clinical reality.
Partner With Us to Co-Develop This Platform